Xact Kapitalforvaltning AB Purchases 21,839 Shares of Celgene Corporation (CELG)
Xact Kapitalforvaltning AB boosted its position in Celgene Corporation (NASDAQ:CELG) by 14.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,725 shares of the biopharmaceutical company’s stock after buying an additional 21,839 shares during the period. Celgene Corporation makes up 0.7% of Xact Kapitalforvaltning AB’s investment portfolio, making the stock its 28th largest position. Xact Kapitalforvaltning AB’s holdings in Celgene Corporation were worth $21,368,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Trexquant Investment LP increased its stake in shares of Celgene Corporation by 110.2% in the fourth quarter. Trexquant Investment LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 2,621 shares during the last quarter. Frontier Wealth Management LLC raised its position in shares of Celgene Corporation by 10.7% in the fourth quarter. Frontier Wealth Management LLC now owns 67,364 shares of the biopharmaceutical company’s stock valued at $7,797,000 after buying an additional 6,508 shares during the period. Marshall Wace LLP raised its position in shares of Celgene Corporation by 492.5% in the fourth quarter. Marshall Wace LLP now owns 469,511 shares of the biopharmaceutical company’s stock valued at $54,346,000 after buying an additional 390,266 shares during the period. Elkfork Partners LLC bought a new position in Celgene Corporation during the fourth quarter worth approximately $80,737,000. Finally, Aviva PLC raised its position in Celgene Corporation by 5.5% in the fourth quarter. Aviva PLC now owns 613,255 shares of the biopharmaceutical company’s stock worth $71,027,000 after buying an additional 31,735 shares during the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.
Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.78% during mid-day trading on Thursday, hitting $135.90. 2,838,895 shares of the stock traded hands. The company has a market cap of $106.32 billion, a P/E ratio of 42.20 and a beta of 1.89. The firm has a 50 day moving average of $132.00 and a 200 day moving average of $123.32. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the company posted $1.44 earnings per share. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.
CELG has been the subject of a number of analyst reports. Jefferies Group LLC set a $154.00 price target on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. Vetr lowered Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 price objective for the company. in a research note on Thursday, May 11th. BTIG Research reissued a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research note on Monday, May 1st. Cantor Fitzgerald set a $159.00 price target on Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, Cann restated a “buy” rating on shares of Celgene Corporation in a research report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $147.06.
In related news, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders sold 227,755 shares of company stock valued at $30,368,142 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.